{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:36:43Z","timestamp":1790800603473,"version":"4.1.0"},"reference-count":12,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p> Erosive lichen planus is a chronic auto-inflammatory disease which affects the stratified squamous epithelia resulting in painful ulcerations of both the skin and mucosal surfaces, and has a known malignant potential. Management of erosive lichen planus has proven to be difficult; however, recent reports of treatment with Janus kinase inhibitors such as Upadacitinib, are encouraging. This report outlines the third reported case of erosive lichen planus to be successfully treated with Upadacitinib in a 70-year-old woman with treatment-resistant disease. In addition, we report the complication of oral squamous cell carcinoma which became apparent once the extensive erosive lichen planus had healed. This case report highlights the importance of monitoring for mucosal squamous cell carcinoma in areas affected by erosive lichen planus, as squamous cell carcinoma can mimic the erosions of erosive lichen planus. <\/jats:p>","DOI":"10.1177\/2050313x231213144","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:44:40Z","timestamp":1700203480000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-8604","authenticated-orcid":false,"given":"Fiona M","family":"Landells","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaina","family":"Goudie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"McGrath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Tibbo","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology, Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian DR","family":"Landells","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"bibr1-2050313X231213144","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2116926"},{"key":"bibr2-2050313X231213144","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0040-7"},{"key":"bibr3-2050313X231213144","unstructured":"U.S. FDA approves RINVOQ\u00ae (upadacitinib) to treat adults and children 12 years and older with refractory, moderate to severe atopic dermatitis. News Center, https:\/\/news.abbvie.com\/news\/press-releases\/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm (2022, accessed 19 August 2023)."},{"key":"bibr4-2050313X231213144","unstructured":"Canada A. AbbVie receives Health Canada approval of RINVOQ\u00ae (UPADACITINIB), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis. Cision Canada (2020, accessed 19 August 2023)."},{"key":"bibr5-2050313X231213144","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14612"},{"key":"bibr6-2050313X231213144","unstructured":"Article. Pfizer, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment (accessed 19 August 2023)."},{"issue":"2","key":"bibr7-2050313X231213144","first-page":"318","volume":"34","author":"Hodge JA","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"bibr8-2050313X231213144","unstructured":"Discover RINVOQ\u00ae (upadacitinib). RINVOQ, https:\/\/www.rinvoq.com\/important-safety-information (accessed 19 August 2023)."},{"issue":"12","key":"bibr9-2050313X231213144","volume":"4","author":"Soo J","year":"2016","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"bibr10-2050313X231213144","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1959506"},{"key":"bibr11-2050313X231213144","doi-asserted-by":"publisher","DOI":"10.3390\/oral3030024"},{"key":"bibr12-2050313X231213144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.06.012"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231213144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X231213144","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231213144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:23:02Z","timestamp":1740820982000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X231213144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":12,"alternative-id":["10.1177\/2050313X231213144"],"URL":"https:\/\/doi.org\/10.1177\/2050313x231213144","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"2050313X231213144"}}